Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing...

Related Keywords

Massachusetts ,United States ,Georgia ,Atlanta ,Boston ,Risvodetinib Ik ,Miltonh Werner ,Risvodetinib Risvo ,Alex Lobo ,Stern Investor Relations Inc ,Linkedin ,Youtube ,Inhibikase Therapeutics Inc ,Facebook ,Inhibikase Or Company ,Steam Review ,Division Of Hematologic Malignancies ,Company Contact ,Exchange Commission ,Nasdaq ,Abelson Tyrosine Kinases ,Chief Executive Officer ,Upcoming Milestones ,Hematologic Malignancies ,Meeting Minutes ,Review Team ,Older Adults ,Abelson Tyrosine Kinase ,Abelson Tyrosine ,Multiple System Atrophy ,Private Securities Litigation Reform Act ,Investor Relations ,